Evaluation of pancreatic carcinoma with FDG PET
暂无分享,去创建一个
[1] W. Steinberg. The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.
[2] Y. Yonekura,et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. , 1995, Radiology.
[3] Scott T. Grafton,et al. PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.
[4] H. Gogas,et al. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? , 1998, British Journal of Cancer.
[5] G. Glatting,et al. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] H. Jadvar,et al. Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. , 1999, Clinical nuclear medicine.
[7] L. Traverso,et al. Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. , 1988, Radiology.
[8] S. Hauptmann,et al. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. , 1993, Nuclear medicine communications.
[9] L. Adler,et al. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. , 1998, Clinical nuclear medicine.
[10] D. V. Von Hoff,et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] F. Safi,et al. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. , 1990, Bulletin du cancer.
[12] G. Glatting,et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] S. Sironi,et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. , 1991, Radiology.
[14] A. Mariani,et al. Serum CA 19‐9 in the postsurgical follow‐up of patients with pancreatic cancer , 1987, Cancer.
[15] L. Griffeth,et al. FDG-PET evaluation of indeterminate pancreatic masses. , 1996, Journal of computer assisted tomography.
[16] H. Friess,et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. , 1995, Gut.
[17] D. Pleskow,et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.
[18] U. Buell,et al. 18FDG-positron emission tomography in pancreatic cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] B. Siewert,et al. Teardrop superior mesenteric vein: CT sign for unresectable carcinoma of the pancreas. , 1999, AJR. American journal of roentgenology.
[20] Stephens Cd. Gemcitabine: a new approach to treating pancreatic cancer. , 1998 .
[21] P. Robinson,et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. , 1999, AJR. American journal of roentgenology.
[22] S. Hauptmann,et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. , 1994, Radiology.
[23] R. Bares,et al. PET with fluorine-18 deoxyglucose for pancreatic disease , 1992, The Lancet.
[24] K. Brandt,et al. CT- and US-guided biopsy of the pancreas. , 1993, Radiology.
[25] P. Shreve. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease , 1998, European Journal of Nuclear Medicine.
[26] B. Wood,et al. Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. , 1999, AJR. American journal of roentgenology.
[27] H. Friess,et al. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. , 1995, Radiology.
[28] R. Coleman,et al. Diagnosis of pancreatic carcinoma: role of FDG PET. , 1998, AJR. American journal of roentgenology.
[29] Y. Nishimura,et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] W. Chapman,et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.